Suppr超能文献

非诺多泮是LLC-PK1细胞中多巴胺-1(DA1)受体的部分激动剂。

Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells.

作者信息

Grenader A, Healy D P

机构信息

Department of Pharmacology, Mount Sinai School of Medicine, City University of New York, New York.

出版信息

J Pharmacol Exp Ther. 1991 Jul 1;258(1):193-8.

PMID:1677038
Abstract

Fenoldopam [6-chloro-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2, 3,4,5-tetrahydro-(1H)-3-benzazepine] is a selective dopamine-1 (DA1) agonist with natriuretic/diuretic properties. A component of the natriuretic response to fenoldopam may involve direct DA1 receptor-mediated effects on proximal tubule sodium reabsorption, possibly through stimulation of adenylyl cyclase. Here, we compared the effects of fenoldopam and DA in stimulating cyclic AMP (cAMP) synthesis in LLC-PK1 cells, a renal epithelial cell line that has proximal tubule-like properties and expresses a DA1 receptor linked to stimulation of adenylyl cyclase. Fenoldopam stimulated cAMP accumulation in LLC-PK1 cells in a dose-dependent manner, an effect which could be blocked by the DA1-selective antagonist Sch 23390. Although fenoldopam was more potent than DA (EC50 55.5 +/- 7.75 nM vs. 1.65 +/- 0.64 microM) in stimulating cAMP accumulation in LLC-PK1 cells, the maximum stimulation obtained by fenoldopam was only 37% of the maximum stimulation obtained by DA(Emax 13.0 +/- 2.95 pmol/mg of protein vs. 35.6 +/- 10.19 pmol/mg of protein). Simultaneous incubation of DA and fenoldopam resulted in lower cAMP levels than with DA alone. Incubation of DA with increasing concentrations of fenoldopam produced parallel rightward shifts in the DA dose-response curves. Schild analysis further indicated that fenoldopam acted as a competitive antagonist in the presence of DA, with a pA2 value of 7.38 and a slope of unity. These results indicate that fenoldopam is a partial agonist with low efficacy at DA1 receptors linked to cAMP generation in the LLC-PK1 cells.

摘要

非诺多泮[6-氯-7,8-二羟基-1-(4'-羟基苯基)-2,3,4,5-四氢-(1H)-3-苯并氮杂卓]是一种具有利钠/利尿特性的选择性多巴胺-1(DA1)激动剂。非诺多泮利钠反应的一个组成部分可能涉及DA1受体对近端小管钠重吸收的直接介导作用,可能是通过刺激腺苷酸环化酶实现的。在此,我们比较了非诺多泮和多巴胺在刺激LLC-PK1细胞中环磷酸腺苷(cAMP)合成方面的作用,LLC-PK1细胞是一种具有近端小管样特性且表达与腺苷酸环化酶刺激相关的DA1受体的肾上皮细胞系。非诺多泮以剂量依赖的方式刺激LLC-PK1细胞中的cAMP积累,该效应可被DA1选择性拮抗剂Sch 23390阻断。尽管在刺激LLC-PK1细胞中的cAMP积累方面,非诺多泮比多巴胺更有效(EC50为55.5±7.75 nM,而多巴胺为1.65±0.64 μM),但非诺多泮获得的最大刺激仅为多巴胺获得的最大刺激的37%(Emax为13.0±2.95 pmol/mg蛋白质,而多巴胺为35.6±10.19 pmol/mg蛋白质)。多巴胺和非诺多泮同时孵育导致cAMP水平低于单独使用多巴胺时。用浓度递增的非诺多泮孵育多巴胺会使多巴胺剂量反应曲线平行向右移动。Schild分析进一步表明,在多巴胺存在的情况下,非诺多泮作为竞争性拮抗剂起作用,pA2值为7.38,斜率为1。这些结果表明,非诺多泮是一种在与LLC-PK1细胞中cAMP生成相关的DA1受体上具有低效能的部分激动剂。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验